Actelion bosentan
Executive Summary
Roche no longer has right of first refusal for acquiring the endothelin antagonist from Actelion (1"The Pink Sheet" March 20, p. 16)
You may also be interested in...
Roche Is Discussing Lamifiban Submission Based On Troponin T Substudy
Roche is in discussions with regulatory authorities regarding an indication for its intravenous glycoprotein IIb/IIIa platelet aggregation inhibitor lamifiban, based on a prospective substudy of its pivotal Phase III trial.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials